Introduction: Temozolomide (TMZ) is the first-line drug for glioblastoma (GBM), but it is
limited in clinical use due to the drug resistance, poor brain targeting, and side effects …

Glioblastoma (GBM) is an unmet clinical need characterized by a standard of care (SOC) 5‐
year survival rate of only 5%, and a treatment mostly palliative. Significant hurdles in GBM …

Research and treatment in the nervous system is challenged by many physiological barriers
posing a major hurdle for neurologists. The CNS is protected by a formidable blood brain …

Advances in active targeting drug delivery system (DDS) have revolutionized glioma
diagnosis and therapy. However, the lack of the sufficient targets on glioma cells and limited …

The blood–brain barrier (BBB) and tumor heterogeneity have resulted in abysmally poor
clinical outcomes in glioblastoma (GBM) with the standard therapeutic regimen. Despite …

Highlights•LMWH has drew attention in the tumor treatment for its diversified anti-tumor
activity.•How to avoid the bleeding potential and promote the anti-cancer effect is high …

Taxanes are one type of the most extensively used chemotherapeutic agents to treat
cancers. However, their clinical use is severely limited by intrinsic and acquired resistance …

Glioblastoma (GBM) remains the epitome of aggressiveness and lethality in the spectrum of
brain tumors, primarily due to the blood–brain barrier (BBB) that hinders effective treatment …

Delivering chemotherapeutics by nanoparticles into tumor was influenced by at least two
factors: specific targeting and highly efficient penetrating of the nanoparticles. In this study …

Effective penetration through the blood–brain barrier (BBB) remains a challenge for the
treatment of many brain diseases. In this study, a small molecule, sinapic acid (SA) …